Curis (NASDAQ:CRIS) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Curis (NASDAQ:CRIS) in a report released on Friday. The brokerage issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of Curis in a research note on Tuesday, December 10th.

Curis Stock Down 3.3 %

Shares of NASDAQ CRIS opened at $2.66 on Friday. Curis has a 52-week low of $2.57 and a 52-week high of $17.49. The business’s 50 day moving average is $3.12 and its two-hundred day moving average is $3.99. The firm has a market cap of $22.52 million, a price-to-earnings ratio of -0.34 and a beta of 3.49.

Institutional Investors Weigh In On Curis

A number of hedge funds have recently added to or reduced their stakes in CRIS. Squarepoint Ops LLC acquired a new position in shares of Curis in the fourth quarter worth $35,000. Millennium Management LLC boosted its holdings in Curis by 92.6% in the fourth quarter. Millennium Management LLC now owns 25,557 shares of the biotechnology company’s stock valued at $78,000 after purchasing an additional 12,287 shares during the period. Focused Wealth Management Inc grew its stake in Curis by 9.5% during the 4th quarter. Focused Wealth Management Inc now owns 59,204 shares of the biotechnology company’s stock worth $181,000 after purchasing an additional 5,138 shares in the last quarter. Geode Capital Management LLC increased its holdings in Curis by 27.3% during the 4th quarter. Geode Capital Management LLC now owns 83,129 shares of the biotechnology company’s stock worth $254,000 after purchasing an additional 17,820 shares during the period. Finally, Alyeska Investment Group L.P. acquired a new stake in Curis in the 4th quarter valued at about $607,000. 29.97% of the stock is currently owned by institutional investors and hedge funds.

About Curis

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.